Sam Tabar Is A Renowned Attorney And A Successful Capital Strategist

Sam Tabar is an investment specialist and a revered attorney. Over the years, he has used technology to develop different innovative products and solutions. Sam invested in a startup known as THINX.

This institution offers feminine hygiene items to women in different parts of the world, particularly in Africa. Most underprivileged women regularly miss important activities in their daily lives due to lack of the essential hygiene products during their menstrual cycles.

Sam Tabar has a sound educational background. He is an alumnus of world’s prestigious institutions, Columbia Law School and Oxford University. After graduating, Sam joined Skadden, Arps, Slater, Meager & Flom LLP, a law firm based in New York.

Sam counseled clients on various matters, including investment management agreements, side letters, as well as hedge fund structure and formation, and employment issues. His interest in the investment world superseded his love for law, forcing him to leave his job as an associate. Eventually, he joined the investment world as a specialist lawyer. Later, he became a committed investor.

In his long and successful career, Sam has worked for different leading investment companies. At the Bank of America Merrill Lynch, he worked as the head of capital strategy. In this position, Sam offered fund supervisors with targeted introductions to institutional investors, including pensions, endowments, family offices, funds of funds, and foundations. Learn more about Sam Tabar:

The shrewd entrepreneur has managed a fund of over $2 billion. Additionally, Sam offered advice on the company’s operations, and assisted in building Merrill Lynch’s office teams.

Previously, Sam worked as the head of marketing at Sparx Group, Asia Pacific’s largest independent fund. He was mandated with the duty of supervising all facets of the company’s worldwide marketing efforts. Later, he returned to practice law. He joined Schulte, Roth & Zabel, a successful law firm.

Sam Tabar offers sound financial and investment advice to his clients. His knowledge in the industry is unrivaled considering that he has gained extensive experience by working for different companies. He ensures that every account offers clients solid returns.

Sam’s social media pages shed more light on his career as a respected financial strategist. He interacts with different people through his Instagram, Facebook, and Aboutme pages.

Everything you need to know about End Citizens United

End Citizens United is a political organization that was formed in 1st March 2015 with funding from grassroots donors. Their primary goal is to counter the effects of Citizens United and help transform the campaign finance system in the country. To show candidates, elected officials, the press, and voters how grassroots is fighting the increasing trend of rich people buying their way to power during elections. Their endeavors are essential to establishing a broad coalition in creating campaign reforms and ensuring lawmakers take action.


End Citizens United Mission


As said earlier, their main goal is to counter big money in politics and end the rigged system by electing finance reform activists and coming up with state ballot laws. The chosen individuals will try overturning Citizens United by putting an end to the billionaires who buy their way to power and dark money.


They achieve the mission by


  • Electing people who agree with the reforms


  • Raising the issue of the rigged system and abundant money politics as the number one priority


  • Having grassroots members to demonstrate because of the big money and power in the political system


How they raised four million dollars


Despite being against big money in politics, End Citizens United group is also raising money for the course. According to USA TODAY, they raised more than $4 million three months after they started. They hope to raise $35 million before the midterm Congress elections in 2018. This amount is almost the same with twenty-five million dollars that PAC used in 2016, the first election cycle operating. The PAC president Tiffany Muller said that more than one hundred thousand people were the contributors to PAC during the first four months of the year. Out of those, 40000 were first timers. The objective of the group is to take “campaign-finance reform champions” to Congress. He added that the average contribution to PAC in 2017 is $12. The contributors to the group feel that the system is against them, and only rich people have the biggest influence. Supporting the group is a way of fighting back.


End Citizens United supporting Democrats


The group supports Democrats in the main races that are for reforms in the campaign finance system. The individuals who will help change the Citizens United. Mostly it is people attacked by mega-donors, wealthy corporates, and dark money groups. The reason the group supports Democrats is that they believe they can bring a meaningful change in leadership. Although there are Republicans who support the course, the Republicans in Congress are standing in the way of these reforms.


In conclusion, End Citizens United group believe the broken system has to end. Candidates who are interested in this can always contact them for more information.


Mikhail Blagosklonny Is Making Profound Impact on Oncology

Mikhail Blagosklonny is an accomplished scientist, physician, scholar, writer, and professor in medicine and oncology. He took his medical studies at First Pavlov State Medical University of St. Petersburg, where he obtained a Master’s Degree in Internal Medicine and a PhD in Experimental Medicine and Cardiology.

Mikhail began practicing as an associate professor of medicine in New York Medical College, Valhalla in 2002 and later was taken in by Ordway Research Institute as a senior scientist. On the 15th April, 2009, Blagosklonny got a coveted appointment as the Professor of Oncology in Roswell Park Cancer Institute. His research on cancer and its therapies, Biogerontology; mechanism of aging and advocacy on the use of Rapamyclin as a cancer and anti-aging drug to elongate life, are some of the remarkable work he has done in medicine. Read more about Mikhail at LinkedIn

Mikhail Blagosklonny talks of the possible role in aging where he outlines the correlation between a cellular system that control growth of cells, development and aging subject to dynamic external environment with varying factors such as nutrient availability, energy levels, growth factors and physiological stresses. He argues that it relays signals of these changes, from which a regulatory action in growth and metabolism is taken in all eukaryotic cells. Rapamycin has been proven to inhibit growth of cells and therefore can be used in cancer treatment to prevent growth or rejuvenation of cancer cells.

This renowned oncologist and scholar has brought forth more than 270 publication from his research work with over 2500 citations just to show the depth of his work and his passionate desire on ways to eradicate cancer cells.following this, he is a member of the editorial board of Cell Death and Differentiation, an associate editor of cancer Biology and therapy and the Editor in Chief of Oncotarget.

At Roswell Park Cancer Institute, Mikhail Blagosklonny currently holds the prestigious position of a professor of oncology where he continues to teach on cell growth and development. He also does his research while at the center and is continually writing more publications on the same.


George Soros on the Transgender Dilemma

The transgender law within the United States is a very controversial topic. Should people who claim to be of the opposite gender be allowed to use public restrooms that do not match their natural sex at birth? In other words, just because a man says that he is now a woman; should he be allowed to use a woman’s bathroom? This is at the heart of the issue and many people are staunchly divided over it.

Political activist George Soros is not gay nor is he a transgender individual. He is a liberal man who has been married three times and divorced twice. His current wife is 42 years younger than him. As of this writing Soros is 86 (the year is 2017). His wife Tamiko Bolton is 44. So, Soros is an old guy that likes young women (relatively speaking that is).

Anyway, Soros’s life has not been categorized by homosexuality or transgender issues. However, he views their plight in the cultural context as an issue to be addressed. Soros believes in having an open and tolerant society. Even if that means supporting people’s lifestyles that are opposed to his own.

Read more on Snopes about George Soros.

It is not that Soros wants the homosexual lifestyle to become the norm for everyone; he just wants to make sure that no one is suffering from it just because they choose to live in that way. This is one of the major reasons why he supports various pro-homosexual groups such as the GSA and the LGBTQ organizations within the U.S.

For Soros, the situation regarding transgender laws and equality for gays is similar to the Civil Rights Movement. Since Soros supports equality for all minority people he also includes gay and transgender people within this scope. So, he has been known to provide funding for various groups and organizations that are in support of this cause. He wants people to understand that a person should have the right to express themselves and their sexuality in a way that seem fit. They should not be discriminated against because of this stance that they take.

People might not agree with this position but Soros realizes that disagreement is not at the heart of this issue. It simply is about treating minority groups fairly. That is what Soros is trying to accomplish through his support of gay and transgender policies and establishments. Visit to know more about George.

Soros continues to provide support on these issues. He leaves it up to the federal government, states and American citizens to decide how they want to respond to the transgender issue. He does not judge gay and transgender people for making the decision to live in a way that they choose is best for them. Once again, he just wants to ensure that everyone is being treated fairly and given a fair chance.


Under the leadership of able its chief editors Andrei Gudkov from Roswell Park Cancer Institute and Blagosklonny Mikhail, Oncotarget is a peer-review medical journal that covers research in all disciplines. The reviews are done on a weekly basing and are open to access. The famous journal published by Impact Journals was brought to life in 2010 with oncology in mind but its success saw other disciplines introduced. Other disciplines covered by the journal include Cardiology, Pharmacology, Neuroscience, Endocrinology, Metabolism and Cell Biology among others. The weekly releases are normally printed to meet special demands. In its presentation, the journal follows Index Medicus, Scopus and Science Citations in creating abstract and in indexing.

Working towards a vision of spreading scientific results broadly and making such results readily available, the journal has seen the impact factor (IF) grow from 4.784 with a coverage of 493 cities in 2011 grow to 5.008 and 10452 cities covered in 2016. An analysis of the Web of Science Core Collection done in January of 2017 showed that the journal would experience a rise in the Thomson Reuters 2016 for the Impact Factor during the next summer. Download output styles at

Other drivers of the journal include to capitalize on the impact of research through insightful assessment, to bring together knowledge from different specialties and biomedical fields, to try eliminate certain diseases through research in clinical and basic sciences and to allow brilliant innovations to spread the climax of it all being a life without illness. The journal has prominent scientists sit in its publishing board including Carlo Croce and Andrew Schally; a onetime Nobel Prize winner. Other notable members include Alexander Varshavsky, Stephen J. Elledge, Michael N. Hall and Bert Vogelstein who won the most prestigious award ever- The Breakthrough price.

Oncotarget journal is the sponsor of Gordon Research Conference and helps all researchers contribute to the advancement of science. The Journals Office is located in East Quaker Street, Suite 1A Orchard Park, NY 14127. In order to make a submission to the journal one must have both JavaScript and Cookies enabled on their browsers, then create an account with their site at Oncortarget is greatly contributing to the field of science. Oncotarget is also available on Dove Press.

Stem Cell Therapy Offers A New Therapeutic Option For Individuals With COPD

With stem cell therapy for respiratory illnesses, a person’s own stem cells repair the damaged tissue in their lungs. For people with chronic lung diseases, stem cell therapy is a new therapeutic option that has alleviated the symptoms over 70 percent of the patients at the Lung Institute. While stem cell therapy is available at several clinics in the U.S. and Mexico, the Lung Institute encourages people to talk to their doctor about stem cell therapy, which few clinics do. In addition, the Lung Institute’s specially trained physicians and physician’s assistants have done more than 3,000 stem cell procedures since 2013, reveals

Stem cell therapy uses a regenerative medical approach that promotes natural healing, however, it is not guaranteed to work. While most patients see improvement in their breathing and stamina levels, individuals will have different responses to the treatment. The Lung Institute evaluates individuals who are interested in pursuing stem cell therapy at one of their five nationwide clinics; however, they will conduct the free evaluation over the phone if necessary to see if a person is a good candidate for the outpatient procedure. As people with chronic lung diseases read stories about how stem cell therapy changed people’s lives for the better, the Lung Institute is receiving an increasing number of inquiries.

Gripping testimonials ( from Lung Institute patients who underwent stem cell therapy underscore how difficult everyday activities are with a chronic lung disease. Joseph O.’s pulmonary fibrosis kept him from standing long enough to brush his teeth, but now, his stamina is back. Ronnie G’s COPD ( and emphysema was so bad that he was considering a lung transplant, however, he decided to try stem cell therapy first, which is continuing to make him feel better and he breathes easier now.

Follow the Lung Institute on Twitter.